Edition:
United States

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

29.47EUR
6:14am EDT
Change (% chg)

€-0.02 (-0.07%)
Prev Close
€29.49
Open
€29.50
Day's High
€29.54
Day's Low
€29.47
Volume
1,041
Avg. Vol
7,489
52-wk High
€44.95
52-wk Low
€24.00

ALCAR.PA

Chart for ALCAR.PA

About

Carmat SAS is a France-based Company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The Company formed a network of partnerships with hospitals and various scientific... (more)

Overall

Beta: 0.94
Market Cap(Mil.): €174.79
Shares Outstanding(Mil.): 5.93
Dividend: --
Yield (%): --

Financials

  ALCAR.PA Industry Sector
P/E (TTM): -- 30.96 17.29
EPS (TTM): -3.81 -- --
ROI: -126.97 12.88 -5.84
ROE: -1,028.47 15.34 -5.23

Carmat buoyed by approval to resume artificial heart trial

Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume a heart implant trial, sending the company's shares more than one fifth higher on Wednesday.

May 03 2017

UPDATE 2-Carmat buoyed by approval to resume artificial heart trial

May 3 Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume a heart implant trial, sending the company's shares more than one fifth higher on Wednesday.

May 03 2017

Carmat gets approval to resume artificial heart implants trial

May 2 Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume heart implant trials, the company said on Tuesday.

May 02 2017

BRIEF-Carmat FY net loss widens to 23 million euros

* Solid cash position of 31.2 million euros ($33.13 million) at December 31, 2016

Feb 14 2017

Carmat withdraws initial request to resume artificial heart implants

Artificial heart maker Carmat said on Monday it had decided to withdraw its initial request to France's national drugs agency (ANSM) to resume trial implantations.

Feb 06 2017

Carmat withdraws initial request to resume artificial heart implants

Feb 6 Artificial heart maker Carmat said on Monday it had decided to withdraw its initial request to France's national drugs agency (ANSM) to resume trial implants.

Feb 06 2017

Carmat shares slump after France halts heart implants

PARIS Shares in artificial heart maker Carmat slumped on Thursday after France's national drugs agency ordered it to suspend further implants following the death of a patient in October.

Dec 01 2016

French drugs agency suspends new Carmat artificial heart implants

PARIS France's national drugs agency said on Wednesday it had ordered artificial heart maker Carmat to suspend further implants after a fifth patient died in October.

Nov 30 2016

More From Around the Web

Earnings vs. Estimates